Hyperimmune immunoglobulin (University of Minnesota)

超免疫球蛋白（明尼苏达大学）

Report date: 2026/05/21 20:00:22

Base Information

Drug NameHyperimmune immunoglobulin (University of Minnesota)

Drug Alias NameHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (University of Minnesota)Anti-Coronavirus Immunoglobulin (ITAC) (University of Minnesota)

ClassificationBiologics > Blood components

Mechanisms of ActionImmunoglobulin modulators

TargetsImmunoglobulin

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus InfectionsSevere Acute Respiratory Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUkraineUganda +[16]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Minnesota

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Minnesota

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Coronavirus Infections

Inactive IndicationsSevere Acute Respiratory Syndrome

Other Information

ATC CodeN/A